Intravenous delivery of an endostatin gene complexed in cationic lipid inhibits systemic angiogenesis and tumor growth in murine models

被引：13

作者：

Blezinger P. ^{[1
]}

Yin G. ^{[2
]}

Xie L. ^{[2
]}

Wang J. ^{[1
]}

Matar M. ^{[1
]}

Bishop J.S. ^{[1
]}

Min W. ^{[1
,2
]}

机构：

[1] Valentis Inc., 8301 New Trials Drive, The Woodlands

[2] Center for Cardiovascular Research, Box 679, Univ. of Rochester Medical Center, 601 Elmwood Avenue, Rochester

来源：

Angiogenesis | 1999年 / 3卷 / 3期

关键词：

Antiangiogenesis; Cationic lipid; Endostatin; Gene therapy; Intravenous delivery;

D O I：

10.1023/A:1009073028842

中图分类号：

学科分类号：

摘要：

Inhibition of the neovascularization of tumors has proven efficacious in reducing tumor growth and metastases. Attaining antiangiogenesis through cationic lipid-based systemic gene therapy presents an attractive approach to the treatment of disseminated and primary cancers. Intravenous administration of an endostatin plasmid, complexed with a cationic lipid system, produced significant levels of endostatin in the lung and the circulation. The expressed endostatin blocked systemic angiogenesis and inhibited tumor growth in murine models. Cytokine induction by cationic lipid/DNA complex increased the anti-tumor activities of endostatin. These results demonstrate the possibility of using cationic lipid delivery of an antiangiogenic gene for cancer treatment.

引用

页码：205 / 210

页数：5

共 23 条

[1]

Hayes, A.J., Li, L.Y., Lippman, M.E., Science, medicine, and the future. Antivascular therapy: A new approach to cancer treatment (1999) BMJ, 318, pp. 853-856

[2]

O'Reilly, M.S., Holmgren, L., Shing, Y., Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma (1994) Cell, 79, pp. 315-328

[3]

O'Reilly, M.S., Boehm, T., Shing, Y., Endostatin: An endogenous inhibitor of angiogenesis and tumor growth (1997) Cell, 88, pp. 277-285

[4]

Folkman, J., Antiangiogenic gene therapy (1998) Proc Natl Acad Sci USA, 95, pp. 9064-9066

[5]

Crystal, R.G., The body as a manufacturer of endostatin (1999) Nat Biotechnol, 17, pp. 336-337

[6]

Kong, H.L., Hecht, D., Song, W., Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor (1998) Hum Gene Ther, 9, pp. 823-833

[7]

Lin, P., Buxton, J.A., Acheson, A., Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2 (1998) Proc Natl Acad Sci USA, 95, pp. 8829-8834

[8]

Tanaka, T., Cao, Y., Folkman, J., Fine, H.A., Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA (1998) Cancer Res, 58, pp. 3362-3369

[9]

Nguyen, J.T., Wu, P., Clouse, M.E., Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy (1998) Cancer Res, 58, pp. 5673-5677

[10]

Xu, M., Kumar, D., Stass, S.A., Mixson, A.J., Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo (1998) Mol Genet Metab, 63, pp. 103-109

← 1 2 3 →